Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility

Abstract

The present invention provides an effective method for inhibiting antro-duodenal motility in healthy subjects and patients suffering from various disorders, without the side effects associated with other pharmaceutical compositions. GLP-1 slows antro-duodenal motility and may be used for the treatment or prevention of gastrointestinal disorders such as diarrhea, postoperative dumping syndrome and irritable bowel syndrome, and also premedication in endoscopic procedures.

1 . A method for inhibiting antro-duodenal motility in a patient in need thereof, which comprises administering to the patient a therapeutically effective amount of a GLP-1 molecule.  
     
     
         2 . The method for inhibiting antro-duodenal motility in  claim 1 , wherein said GLP-1 molecule is a GLP-1(7-36)amide.  
     
     
         3 . A dosage unit for use in inhibiting antro-duodenal motility in a patient comprising GLP-1 and a pharmaceutically suitable excipient.  
     
     
         4 . The dosage unit of  claim 3 , wherein dose of said GLP-1 molecule is in the range of about 0.4-2.4 pmol·kg −1 ·min −1 .  
     
     
         5 . The dosage unit of  claim 4 , wherein dose of said GLP-1 molecule is in the range of about 0.8-1.2 pmol·kg −1 ·min −1 .  
     
     
         6 . The dosage unit of  claim 3 , wherein said pharmaceutically suitable excipient is orally, parenterally or subcutaneously acceptable.  
     
     
         7 . The dosage unit of  claim 3 , wherein said pharmaceutically suitable excipient is intravenously acceptable.  
     
     
         8 . A method for premedicating in endoscopic procedures, which comprises administering to the patient a therapeutically effective amount of a GLP-1 molecule.  
     
     
         9 . The method for premedicating in endoscopic procedures  claim 8 , wherein said GLP-1 molecule is a GLP-1(7-36)amide.  
     
     
         10 . A method for treating or preventing non-infectious acute or chronic diarrhea in a patient in need thereof which comprises administering to the patient a therapeutically effective amount of a GLP-1 molecule.  
     
     
         11 . The method for treating or preventing non-infectious acute and chronic diarrhea in  claim 10 , wherein said GLP-1 molecule is a GLP-1(7-36)amide.  
     
     
         12 . A method for treating or preventing postoperative dumping syndrome in a patient in need thereof, which comprises administering to the patient a therapeutically effective amount of a GLP-1 molecule.  
     
     
         13  The method for treating or preventing postoperative dumping syndrome in  claim 12 , wherein said GLP-1 molecule is a GLP-1(7-36)amide.  
     
     
         14 . A method for treating or preventing irritable bowel syndrome in a patient in need thereof, which comprises administering to the patient a therapeutically effective amount of a GLP-1 molecule.  
     
     
         15 . The method for treating or preventing irritable bowel syndrome in  claim 14 , wherein said GLP-1 molecule is a GLP-1(7-36)amide.  
     
     
         16 . A method for treating or preventing symptoms associated with narcotics withdrawal in a patient in need thereof, which comprises administering to the patient a therapeutically effective amount of a GLP-1 molecule.  
     
     
         17 . The method for treating or preventing symptoms associated with narcotics withdrawal in  claim 16 , wherein said GLP-1 molecule is a GLP-1(7-36)amide.  
     
     
         18 . A method according to  claim 1 , wherein said GLP-1 molecule is administered orally or parenterally.